Product Name: CFHR5 Antibody
Species Reactivity: Human
Tested Applications: Flow, IHC-P, WB
Applications: For WB starting dilution is: 1:1000For IHC-P starting dilution is: 1:10~50For FACS starting dilution is: 1:10~50
User Note: Optimal dilutions for each application to be determined by the researcher.
Predicted Molecular Weight: 64 kDa
Immunogen: This CFHR5 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 203-231 amino acids from the Central region of human CFHR5.
Host Species: Rabbit
Purification: This antibody is purified through a protein A column, followed by peptide affinity purification.
Physical State: Liquid
CAS NO.: 107-35-7
Product: Taurine
Buffer: Supplied in PBS with 0.09% (W/V) sodium azide.
Concentration: 0.5 mg/ml
Storage Conditions: Store at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Clonality: Polyclonal
Conjugate: Unconjugated
Alternate Names: Complement factor H-related protein 5, FHR-5, CFHR5, CFHL5, FHR5
Accession NO.: Q9BXR6
Protein Ino: 23396597
Official Symbol: CFHR5
Geneid: 81494
Background: CFHR5 is a member of a small complement factor H (CFH)gene cluster on chromosome 1. Each member of this gene familycontains multiple short consensus repeats (SCRs) typical ofregulators of complement activation. The protein encoded by thisgene has nine SCRs with the first two repeats having heparinbinding properties, a region within repeats 5-7 having heparinbinding and C reactive protein binding properties, and theC-terminal repeats being similar to a complement component 3 b(C3b) binding domain. This protein co-localizes with C3, binds C3bin a dose-dependent manner, and is recruited to tissues damaged byC-reactive protein. Allelic variations in this gene have beenassociated, but not causally linked, with two different forms ofkidney disease: membranoproliferative glomerulonephritis type II(MPGNII) and hemolytic uraemic syndrome (HUS). [provided byRefSeq].
PubMed ID:http://aac.asm.org/content/35/11/2447.abstract
